Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014 Aug 16:10:651-64.
doi: 10.2147/TCRM.S57509. eCollection 2014.

Advanced prostate cancer - patient survival and potential impact of enzalutamide and other emerging therapies

Nihar K Patel  1 , Antoine Finianos  1 , Kristen D Whitaker  1 , Jeanny B Aragon-Ching  1
Affiliations
Review

Advanced prostate cancer - patient survival and potential impact of enzalutamide and other emerging therapies

Nihar K Patel et al. Ther Clin Risk Manag. .

Abstract

The advent of exponential growth of novel agents tested and approved for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) has brought about a need for understanding of the mechanism of action, side-effects, and clinical efficacy of these drugs as they relate to these patients. This review will provide a synopsis of the treatment landscape in mCRPC as varying agents such as abiraterone acetate, cabazitaxel, sipuleucel-T, radium, and selected emerging agents are presented. A distinct focus on the utilization of enzalutamide, its mechanism of action, key pivotal trials that brought about its US Food and Drug Administration approval, as well as patient-focused perspectives and clinical implications are discussed herein.

Keywords: enzalutamide; metastatic castration-resistant prostate cancer; systemic therapies.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Mechanism of action of enzalutamide. Note: Enzalutamide inhibits binding of testosterone to the AR, prevents translocation, impairment of AR DNA binding, and interference with co-activator recruitment and DNA transcription.
See this image and copyright information in PMC

References

    1. Siegel R, Ma J, Zou Z, et al. Cancer statistics, 2014. CA Cancer J Clin. 2014;64(1):9–29. - PubMed
    1. Mohler JL, Kantoff PW, Armstrong AJ, et al. Prostate cancer, version 1. 2014. J Natl Compr Canc Netw. 2013;11(12):1471–1479. - PubMed
    1. Cookson MS, Roth BJ, Dahm P, et al. Castration-resistant prostate cancer: AUA Guideline. J Urol. 2013;190(2):429–438. - PubMed
    1. Mezynski J, Pezaro C, Bianchini D, et al. Antitumour activity of docetaxel following treatment with the CYP17A1 inhibitor abiraterone: clinical evidence for cross-resistance? Ann Oncol. 2012;23(11):2943–2947. - PubMed
    1. Noonan KL, North S, Bitting RL, et al. Clinical activity of abiraterone acetate in patients with metastatic castration-resistant prostate cancer progressing after enzalutamide. Ann Oncol. 2013;24(7):1802–1807. - PubMed

LinkOut - more resources